Cancer Chemotherapy and Pharmacology

, Volume 14, Issue 1, pp 42–48

Human pharmacokinetics of marcellomycin

  • P. Dodion
  • M. Rozencweig
  • C. Nicaise
  • M. Watthieu
  • J. M. Tamburini
  • C. E. RiggsJr.
  • N. R. Bachur
Original Articles Marcellomycin


In conjunction with two phase I clinical trials, we have investigated the pharmacokinetics of marcellomycin (MCM), a new class II anthracycline antibiotic, in nine patients with normal renal and hepatic functions and no third-space fluid accumulation. MCM was infused IV over 15 min at a dosage of 27.5, 40, or 50 mg/m2. Plasma and urine samples were collected up to 72 h. MCM and metabolites were assayed by thin-layer chromatography and quantified by specific fluorescence. The disappearance of total MCM-derived fluorescence from plasma followed first-order kinetics and lacked the rebound in total fluorescence that has been described for the structurally similar agent, aclacinomycin A. After 40–50 mg/m2, the peak MCM concentration in plasma was 1.67±0.61 μM; MCM disappeared from plasma in a triexponential fashion and was undetectabel by 48 h after infusion. The area under the plasma concentration-time plot (AUC), including the infusion time, was 1.11±0.39 μMxh; plasma clearance of MCM was 1.50±0.88 l/min/m2. Five other fluorescent compounds were consistently observed in plasma. M2 was a contaminant present in the parent drug. P1 and P2 were conjugates of MCM and M2, respectively. G1 and G2 were aglycones. The peak concentrations of the metabolites were 25% or less or the peak concentration for MCM, but their persistence resulted in higher AUCs than that for MCM. For the dosage of 27.5 mg/m2, fewer data were available; but the pharmacokinetics of MCM and metabolites appeared to be similar to that at higher dosage. Urinary excretion of total fluorescence amounted to 8.0%±1.6% of the total dose at 40–50 mg/m2, and to 7.0%±2.3% at 27.5 mg/m2. No correlation was detected among the various pharmacokinetic parameters and toxicities encountered in these patients.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Andrews PA, Brenner DE, Chou FE, Kubo H, Bachur NR (1980) Facile and definitive determination of human adriamycin and daunorubicin metabolites by high-pressure liquid chromatography. Drug Metab Dispos 8:152Google Scholar
  2. 2.
    Benjamin RS (1981) Clinical pharmacology of daunorubicin. Cancer Treat Rep [Suppl 4] 65:109Google Scholar
  3. 3.
    Benjamin RS, Riggs CE, Bachur NR (1977) Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Res 37:1416Google Scholar
  4. 4.
    Bradner WT, Huftalen JB (1978) Marcellomycin: an anthracycline without leukopenic effect in BDF1 mice. Proc Am Assoc Cancer Res 19:46Google Scholar
  5. 5.
    Chang B, Dodion P, Tamburini JM, Riggs CE, Bachur NR (1983) In vitro metabolism of marcellomycin. Proc Am Assoc Cancer Res 24:258Google Scholar
  6. 6.
    Crooke ST, Duvernay VH, Galvan L, Prestayko AW (1978) Structure-activity relationships of anthracyclines relative to effect on macromolecular syntheses. Mol Pharmacol 14:290Google Scholar
  7. 7.
    Dodion P, Egorin MJ, Tamburini JM, Riggs CE, Bachur NR (1983) The murine metabolism and disposition of marcellomycin. Proc Am Assoc Cancer Res 24:254Google Scholar
  8. 8.
    Driscoll JS, Hazard GF, Wood HB, Goldin A (1974) Structure-antitumor activity relationships among quinone derivatives. Cancer Chemother Rep 4:1Google Scholar
  9. 9.
    Egorin MJ, Van Echo D, Fox BM, Whitacre M, Bachur NR (1982) Plasma kinetics of aclacinomycin A and its major metabolites in man. Cancer Chemother Pharmacol 8:41Google Scholar
  10. 10.
    Egorin MJ, Andrews PA, Nakazawa H, Bachur NR (1983) Purification and characterization of aclacinomycin A and its metabolites from human urine. Drug Metab Dispos 11:167Google Scholar
  11. 11.
    Fourcade A, Farhi JJ, Bennoun M, Goldschmidt E, Tapiero H (1983) Fate of aclacinomycin-A and its metabolites effect on cell growth and macromolecular synthesis. Biochem Pharmacol 32:1819Google Scholar
  12. 12.
    Gibaldi M, Perrier D (1982) Multicompartment models. In: Pharmacokinetics. Dekker, New York, p 45Google Scholar
  13. 13.
    Joss RA, Kaplan S, Goldhursh A, Varini M, Brunner KW, Cavalli F (1983) A phase I trial of marcellomycin with a weekly dose schedule. Eur J Cancer Clin Oncol 19:455Google Scholar
  14. 14.
    Nettleton DE, Bradner WT, Bush JA, Coon AB, Moseley JE, Myllymaki RW, O'Herron FA, Schreiber RH, Vulcano AL (1977) New antitumor antibiotics: musettamycin and marcellomycin from bohemic acid complex. J Antibiot (Tokyo) 30:525Google Scholar
  15. 15.
    Nicaise C, Rozencweig M, DeMarneffe M, Crespeigne N, Dodion P, Piccart M, Sculier JP, Lenaz L, Kenis Y (1983) Clinical phase I trial with marcellomycin with a single-dose schedule. Eur J Cancer Clin Oncol 19:449Google Scholar
  16. 16.
    Oki T, Takeuchi T, Oka S, Umezawa H (1980) New anthracycline antibiotic aclacinomycin A: experimental studies and correlations with clinical trials. Recent Res Cancer Res 76:22Google Scholar
  17. 17.
    Ozols RF, Willson JKV, Weltz MD, Grotzinger KR, Myers CE, Young RC (1980) Inhibition of human ovarian cancer colony formation by adriamycin and its major metabolites. Cancer Res 40:4109Google Scholar
  18. 18.
    Reich SD, Bradner WT, Rose WC, Schurig JE, Madissoo H, Johnson DF, DuVernay VH, Crooke ST (1980) Marcellomycin. In: ST Crooke, SD Reich (eds) Anthracyclines: Current status and new development. Academic Press, New York, p 343Google Scholar
  19. 19.
    Robert J, Hoerni B, Vrigaud P, Lagarde C (1983) Early-phase pharmacokinetics of doxorubicin in non-Hodgkin lymphoma patients. Cancer Chemother Pharmacol 10:115Google Scholar
  20. 20.
    Rozencweig M, Nicaise C, Dodion P, Piccart M, Bron D, Mattelaer M, Dumont G, Atassi G, Strijkmans P, Kenis Y (1981) Marcellomycin: preclinical and clinical aspects. In: FW Muggia, CW Young, SK Carter (eds) Anthracycline antibiotics in cancer therapy. Nijhoff, The Hague, p 549Google Scholar
  21. 21.
    Young RC, Ozols RF, Myers CE (1981) The anthracycline antineoplastic drugs. N Engl J Med 305:139Google Scholar

Copyright information

© Springer-Verlag 1985

Authors and Affiliations

  • P. Dodion
    • 3
  • M. Rozencweig
    • 2
  • C. Nicaise
    • 2
  • M. Watthieu
    • 2
  • J. M. Tamburini
    • 1
  • C. E. RiggsJr.
    • 2
  • N. R. Bachur
    • 3
  1. 1.Division of Developmental TherapeuticsUniversity of Maryland Cancer CenterBaltimoreUSA
  2. 2.Institut Jules BordetBrusselsBelgium
  3. 3.Laboratory of Medicinal Chemistry and Biology, National Cancer Institute, DCTNIHBethesdaUSA

Personalised recommendations